#AACR: Bris­tol-My­ers tunes out sta­t­ic, broad­casts im­pres­sive re­sults for Op­di­vo/Yer­voy lung can­cer com­bo

CHICA­GO — Bris­tol-My­ers Squibb $BMY ran smack dab in­to a high lev­el of pro­fes­sion­al sta­t­ic when it changed up its study de­sign for Check­mate-227, a piv­otal test for Op­di­vo plus Yer­voy in treat­ing new cas­es of non-small cell lung can­cer. But they’ve ar­rived at AACR with da­ta they say spell out a com­pelling case for their PD-1/CT­LA-4 com­bo.

“The da­ta we re­port here are ex­cit­ing,” says Fouad Namouni, the on­col­o­gy de­vel­op­ment chief at Bris­tol-My­ers, “with an im­por­tant lev­el of ac­tiv­i­ty.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER